United Kingdom Softgel Capsules Market

United Kingdom Softgel Capsules Market Summary

As per Transpire Insight Analysis the United Kingdom Softgel Capsules Market size is estimated at USD 274.6 Million in 2025 and is anticipated to reach USD 434.5 Million by 2033, growing at a CAGR of 5.90% from 2026 to 2033.

The United Kingdom softgel capsules market serves pharmaceutical , nutraceutical and wellness makers, by sending active ingredients in a sort of dosage form that eases swallowing, keeps fragile compounds shielded, and makes dosing feel more exact. Softgel know-how is especially helpful for oils , fat soluble vitamins, and specialty blends where stability, uptake in the body, and overall consumer convenience really kind of end up deciding how well a product performs and if it sells well. So, this format becomes a noteworthy delivery system for prescription medicines, dietary supplements, and preventive healthcare items.

Over the past three to five years, the market has leaned more and more toward premium formulations, with “clean” ingredient selections, vegetarian capsule technologies and contract manufacturing partnerships that give even more manufacturing flexibility. After the COVID 19 pandemic, supply chain disruptions highlighted a few weak points in raw material sourcing, so producers pushed to strengthen domestic and nearby supply routes, plus they started putting more money into production resilience. Those changes, sort of, have helped pharma and nutraceutical brands roll out higher value formulations faster, expand their product lines, boost manufacturing utilization, and build better revenue odds across both healthcare and everyday consumer wellness channels.

United Kingdom Softgel Capsules Market Size & Forecast:

• United Kingdom Softgel Capsules Market Size 2025: USD 274.6 Million
• Expected Market Value 2033: USD 434.5 Million
• Forecast CAGR: 5.90%
• Leading region in 2025: England
• Fastest Growing region: Scotland
• Key Profile: Catalent, Capsugel, Sirio Pharma, Aenova, Procaps, Soft Gel Technologies, EuroCaps, NutraScience Labs, Robinson Pharma, Captek Softgel, Fuji Capsule, Patheon, Amway, Nature's Bounty, Haleon 

Key Market Insights

• England kind of dominated the United Kingdom Softgel Capsules Market, with something like 82% market share in 2025 , and that was mostly backed by concentrated pharmaceutical manufacturing plus nutraceutical production spaces .
• Scotland is expected to show the fastest growth across 2025–2032 , mainly because life sciences investment is increasing and contract development and manufacturing capabilities keep getting broader , and yes that momentum matters .
• For the product split, gelatin softgel capsules took the lead with roughly 64% market share in 2025, which points to solid pharmaceutical acceptance and an already mature manufacturing backbone.
• Vegetarian softgel capsules were placed second , and they seem to benefit from clean-label supplement portfolios expanding, along with consumer formulation preferences that are evolving a bit .
• Plant-based softgel technologies are forecast to record the fastest growth through 2032, supported by innovation in carrageenan and starch-based encapsulation materials and related alternatives .
• When it comes to applications, nutraceutical use was in front with around 57% market share in 2025, as premium vitamins , omega-3, and specialty wellness formulations continued widening retail reach.
• Prescription pharmaceutical applications are predicted to grow fastest through 2032 , because these products need more complex drug delivery , plus ongoing formulation improvements that are hard to simplify.
• On the end-user side, pharmaceutical manufacturers represented the leading group, with about 61% market share in 2025, largely driven by high-volume production and regulated product pipelines .
• Meanwhile CDMOs , or contract development and manufacturing organizations , are projected to be the fastest-growing end-user category during 2025–2032, reflecting outsourcing habits and flexible manufacturing strategies .

What are the Key Drivers, Restraints, and Opportunities in the United Kingdom Softgel Capsules Market?

The primary driver is the shift toward complex oral formulations that need higher bioavailability and some ingredient safeguarding. Improvements in lipid based delivery systems and premium nutraceutical preparations have pushed faster adoption because manufacturers can make the ingredient stability better while still facing fewer formulation hiccups. Regulatory focus on product quality and consistent dosing has then nudged companies to invest in modern encapsulation hardware. So as firms roll out higher value pharmaceutical and wellness items, the average product value climbs together with manufacturing use, and that in turn supports stronger revenue all along the supply chain.

The principal restraint is dependence on specialized raw inputs and a limited amount of high capacity manufacturing setup. To grow output you typically need hefty capex, regulatory sign off, and also skilled technical know-how, which slows down any quick expansion of capacity. Based on a Transpire Insight review of regional procurement announcements plus launch timelines, supply chain concentration stays the main execution risk. Qualification periods that run longer can push commercial launches back by several months which reduces production agility and also limits revenue capture when demand is at its peak.

A major opportunity sits in next generation vegetarian softgel approaches combined with more advanced contract manufacturing. Pharmaceutical and nutraceutical brands are increasingly asking for tailored encapsulation platforms, for differentiated SKUs. Investment in automation on the production line, continuous quality monitoring, and export oriented manufacturing helps position the United Kingdom as a competitive source for European healthcare markets. Those strengths should enable premium formulations with improved margins and wider international commercialization.

What Has the Impact of Artificial Intelligence Been on the United Kingdom Softgel Capsules Market?

Artificial intelligence and digital manufacturing techs are kind of reshaping softgel capsule production , not just by speeding things up , but by making process control feel more steady, the formulation more consistent, and regulatory compliance less of a headache. A lot of manufacturers now use AI-based vision checking systems to catch capsule defects, keep track of fill accuracy, and notice sealing irregularities before anything gets moved to the packaging lines. And then there are digital quality management platforms , which basically take over the compliance documentation workflow , so less time is spent doing manual review and more time on audit readiness in regulated plants.

Machine learning models also help with demand prediction and shop-floor planning , by mixing past sales, procurement records, and inventory movement. Those foresights help companies fine-tune raw material ordering, ease production slowdowns, and push better equipment use. On top of that, predictive maintenance setups watch encapsulation machines and drying units, so maintenance teams can step in early, before failures start stealing uptime. The overall effect is more operational stability, fewer wasted batches, better yield, and usually lower manufacturing costs across both pharmaceutical and nutraceutical operations.

Still, AI rollouts are limited , mostly due to integration expenses and the fact that manufacturing data is pretty fragmented. Lots of older production sites run equipment without standardized digital connections, so real-time analytics become much harder to pull off. Plus, uneven data quality can weaken prediction results when formulations get changed, which means human validation still stays necessary before automated systems can be trusted for mission-critical choices.

Key Market Trends

• Vegetarian softgel capsule production kind of sped up after 2022, with makers expanding carrageenan and starch based formulations for those premium supplement lineups, sort of.
• AI powered visual inspection systems started replacing the more manual quality checks during 2023–2025 and yeah it improved defect spotting and helped batches stay more consistent.
• Contract manufacturing partnerships also grew across the United Kingdom, between 2022 and 2025 which let companies commercialize specialized pharmaceutical formulations faster, not just slower.
• Catalent upped its investment in newer oral dosage manufacturing technologies to get better production flexibility, and to back more complicated drug delivery programs.
• Lonza kept pushing its formulation know-how forward through tech investments that support higher performance encapsulation solutions for pharmaceutical clients.
• Supply chain diversification became a big deal after pandemic type disruptions, so dependence on single source gelatin and specialty ingredient suppliers went down.
• Continuous manufacturing technologies got more attention in 2024–2025, and that helped reduce production downtime while lifting batch throughput.
• Premium nutraceutical brands leaned more into lipid based delivery systems lately because improved bioavailability supports differentiated product positioning in crowded retail channels.
• Digital batch documentation plus automated compliance systems expanded across regulated manufacturing sites too, which shortened release timelines, while also strengthening regulatory readiness.

United Kingdom Softgel Capsules Market Segmentation

By Type :

Gelatin softgels hold the leading share, because pharmaceutical and nutraceutical manufacturers really like proven performance, dependable sealing and fast, large scale production. There’s also strong alignment with oil-based ingredients, vitamins, and prescription formulations which helps keep commercial demand steady and predictable. Plus the manufacturing methods are already well tried and tested, so production risk comes down , and product quality tends to stay high across many different use cases.

Vegetarian softgels keep growing too, mainly as plant-based formulations get more accepted across healthcare and general wellness categories. Starch softgels, meanwhile, fit more specialized needs , especially when ingredient compatibility or personal dietary preferences make alternative capsule materials make more sense. Other softgel styles also show up for niche therapeutic and nutritional products, letting manufacturers fine tune specific formula goals while still widening their overall product range.

By Application :

Dietary supplements remain the biggest application segment because softgel capsules protect ingredients better, improve dosage accuracy, and make life easier for consumers. Manufacturers often choose this format for vitamins, minerals and specialty nutrition products, where stability really affects whether the final goods perform as expected. New premium supplement releases keep adding momentum, especially across retail and healthcare distribution.

Pharmaceutical uses stay important as well, driven by prescription medicines and more advanced drug delivery designs. In cosmetics, softgel tech gets used for beauty oriented supplements , focused on skin and hair support, and nutraceutical offerings continue expanding through preventive health approaches. Other applications also exist, covering targeted formulations for specific health conditions and newer wellness trends.

By Function :

Vitamin supplements are driving the leading functional segment, mostly because softgel capsules wrap up and protect sensitive nutrients while keeping daily dosing, pretty much on point each day. Fat-soluble vitamins often gain better stability and more dependable delivery, so softgels end up as a go-to dosage format for manufacturers. Ongoing product innovation keeps pushing premium vitamin lineups across the healthcare and wellness scene, even when tastes change a bit over time.

Omega-3 products are still another big category, because encapsulation helps keep the oil quality steady and also stretches shelf life. Herbal products and probiotic formulations continue to grow, since manufacturers keep rolling out more differentiated health solutions, with stronger ingredient protection. Other functional offerings cover specialized nutritional needs too, using targeted formulation approaches that support portfolio diversification and more flexible positioning.

By Distribution Channel :

Pharmacies lead distribution, largely because both healthcare professionals and consumers keep trusting retail channels for prescription medicines and nutritional supplements. Broad product availability plus regulated dispensing habits help strengthen purchasing confidence across pharmaceutical and wellness categories. Plus, established pharmacy networks tend to reinforce premium product placement and repeat sales.

Online retail also shows strong expansion, thanks to easier purchasing, a wider assortment, and direct-to-consumer operating models. Supermarkets boost access for everyday wellness items, while specialty stores lean into premium nutrition and healthcare solutions. Additional distribution avenues add more reach through institutional sales and a few selected commercial partnerships.

By End User :

Adults show up as the biggest end-user slice, largely because preventive healthcare, nutritional supplementation, and these long term wellness programs keep supporting a steady, kind of consistent product use. Softgel capsules are also a win for simple administration, plus they keep dosing dependable, so regular usage feels practical for multiple health categories. On top of that, product innovation basically nudges wider adoption, via specialized formulations meant for a variety of day to day lifestyle needs.

At the geriatric end, it grows at a steady pace too, since nutritional demands tied to aging create openings for targeted formulations, often with easier swallowing characteristics. For pediatric products, they back selected healthcare uses, where formulation design helps make administration more smooth and acceptance higher. Meanwhile, the other end-user categories still add demand, mostly through condition specific nutritional and therapeutic requirements.

By Source :

Animal based softgel capsules are still leading the segment, because gelatin technology keeps showing proven manufacturing performance, broad regulatory acceptance and fairly efficient production economics. There’s also good alignment with pharmaceutical and nutraceutical ingredients, so it supports widespread commercial use across already established product categories. On top of that, the existing manufacturing infrastructure keeps adding to the market position via consistent production quality, which is kind of hard to replicate fast.

Meanwhile plant based sources keep recording solid expansion, as manufacturers roll out vegetarian alternatives that match shifting formulation preferences, and help with broader positioning strategies. Improvements in plant derived capsule materials keep boosting performance too, while also backing premium product development plans. Other source materials are also moving in, especially for specialized formulation needs, where unique ingredient compatibility or technical performance creates extra commercial opportunities.

What are the Key Use Cases Driving the United Kingdom Softgel Capsules Market?

The main leading use case kind of comes from dietary supplements, where softgel capsules are used to deliver vitamins, omega-3 oils and other lipid based ingredients, in a way that keeps the dosage consistent and helps with long term product stability. Pharmaceutical companies, supplement brands, pharmacies and healthcare retailers buy these products because easy administration tends to drive solid consumer acceptance, and yes it also helps repeat purchases.

On the manufacturing side, pharmaceutical manufacturers are increasing the use of softgels for prescription medicines, especially those that need improved absorption and better protection for sensitive active ingredients. In a similar direction, cosmetics and nutraceutical producers are taking on softgel delivery for beauty from within concepts, plus more focused wellness formulations aimed at adults, and also geriatric consumers who are looking for premium health solutions.

More emerging applications show up too, like probiotic formulations and specialized herbal products, developed with advanced encapsulation technologies that help preserve ingredient viability. Plant based softgel formats also show long term potential, as manufacturers respond to changing formulation standards and regulatory expectations for alternative capsule materials across both healthcare and nutrition industries.

Which Regions are Driving the United Kingdom Softgel Capsules Market Growth?

England sits at roughly 82% of the market, and still sort of leads the regional side of things, without real competition. Stringent pharmaceutical rules, high-level manufacturing practices, and a fairly mature life sciences environment help keep softgel capsule production and commercialization moving in a steady way. There are concentrated manufacturing sites, plus contract development organizations, ingredient providers, and research collaborations, and together they form a pretty efficient supply chain that can handle big, on-going scale. If investment keeps going into formulation know-how, production automation, and broader healthcare innovation then regional leadership should keep holding steady during the whole forecast span.

Scotland is the second-largest regional market , largely because its expansion gets powered more by a solid life sciences research foundation than by pure manufacturing capacity. Public backing for biotechnology stays fairly consistent, regulatory adherence is steady, and long-term funding for pharmaceutical novelty gives fairly dependable conditions for businesses. When research institutions work with commercial manufacturers, product development becomes more streamlined, while also backing specialized formulation work. Those built-in strengths end up supporting reliable revenue generation and also lowering the risk from short term swings in the market.

Scotland is also expected to see the most rapid growth during 2026–2033, as fresh investments in pharmaceutical manufacturing capacity and contract development services ramp up commercial activity. With extra life sciences infrastructure and higher take up of advanced production technologies, the region has improved its ability to support high-value formulations. There’s also more backing for plant based capsule technologies, plus export driven manufacturing, which pretty much reinforces the growth outlook. All this momentum should, in turn, open appealing opportunities for makers, tech providers and investors who are after expansion across premium pharmaceutical and nutraceutical output.

Who are the Key Players in the United Kingdom Softgel Capsules Market and How Do They Compete?

Competition stays sort of moderately consolidated, because global manufacturers move alongside specialized contract development and manufacturing organizations, even if it feels a bit messy at times. Technology innovation, formulation, knowing how manufacturing quality and customized production services are basically the main things driving rivalry. Incumbent manufacturers keep tightening production capacity and specialized delivery technologies, then at the same time expanding contract manufacturing which opens room for firms that deliver more flexible development and commercialization support.

Catalent puts emphasis on advanced formulation technologies plus large scale manufacturing services, so pharmaceutical customers can compress development timelines. **Lonza** stands apart using dedicated encapsulation know how, integrated development capabilities, and continued spending on modern oral dosage technologies. **Aenova Group** leans into bespoke formulation development and adaptable manufacturing solutions, aimed at pharmaceutical and nutraceutical customers who need more complex production capabilities.

Sirio Pharma pushes growth through higher end nutraceutical product development and wider European manufacturing coverage, this helps them respond quicker to changing customer needs. Procaps Group improves its position by widening contract manufacturing services and keeping diversified formulation platforms, targeting healthcare companies that want outsourcing partners. **EuroCaps** concentrates on customized softgel production for nutritional products, and they create value via formulation flexibility, responsive manufacturing plus customized customer support, which then helps with specialized product requirements.

Company List

• Catalent
• Capsugel
• Sirio Pharma
• Aenova
• Procaps
• Soft Gel Technologies
• EuroCaps
• NutraScience Labs
• Robinson Pharma
• Captek Softgel
• Fuji Capsule
• Patheon
• Amway
• Nature's Bounty
• Haleon 

Recent Development News

In February 2026, Catalent and S.Biomedics announced a strategic partnership to develop and manufacture the TED-A9 cell therapy candidate. The collaboration expands Catalent's advanced manufacturing capabilities and reinforces CDMO investment that supports pharmaceutical production technologies relevant to the softgel and oral dosage manufacturing ecosystem. Sourcehttps://www.catalent.com/

In June 2025, GenSight Biologics expanded its manufacturing partnership with Catalent by successfully transferring the upstream manufacturing process for LUMEVOQ® to Catalent. The milestone strengthens high-value pharmaceutical manufacturing capacity and demonstrates continued investment in advanced contract manufacturing services that benefit the broader encapsulation and dosage delivery industry. 

Sourcehttps://www.gensight-biologics.com/

What Strategic Insights Define the Future of the United Kingdom Softgel Capsules Market?

The United Kingdom Softgel Capsules Market is likely to drift toward higher value, technology-led manufacturing , over the next five to seven years, mainly because pharma innovation and specialized nutraceutical formulas need more advanced oral delivery setups. In other words, growth is going to rely less on just adding more capacity, and more on formulation know how, automated output, and the capability to commercialize plant based encapsulation approaches that are also kinda complex. There’s also a risk that’s not as obvious at first glance: the industry may keep leaning on specialized gelatin, functional excipients, and only a few high-capacity production facilities, which could actually limit supply flexibility when big product launches hit.

At the same time, a real opportunity is forming. Next generation plant based softgel technologies are showing up, helped by shifting formulation guidelines and a demand for premium healthcare products. Firms that start early with automated manufacturing, build resilient regional sourcing, and team up via research partnerships with pharmaceutical innovators , should be able to land higher margin agreements sooner and lock in a stronger long-term edge.

United Kingdom Softgel Capsules Market Report Segmentation

By Type

• Gelatin Softgels
• Vegetarian Softgels
• Starch Softgels

By Application

• Dietary Supplements
• Pharmaceuticals
• Cosmetics
• Nutraceuticals

By Function

• Vitamin Supplements
• Omega-3
• Herbal Products
• Probiotics

By Distribution Channel

• Pharmacies
• Online Retail
• Supermarkets
• Specialty Stores

By End User

• Adults
• Geriatric
• Pediatric

By Source

• Animal-Based
• Plant-Based